Eltrapuldencel-T

Drug Profile

Eltrapuldencel-T

Alternative Names: Autologous stem cell therapy - California Stem Cell; Cancer stem cell - California Stem Cell; CLBS 20; DC-TC; DC/DT; MAC-VAC; Malignant melanoma stem cell therapy - NeoStem Oncology; Melapuldencel-T; NBS 20

Latest Information Update: 06 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hoag Memorial Hospital Presbyterian
  • Developer Caladrius Biosciences
  • Class Cancer vaccines; Dendritic cell vaccines; Immunotherapies; Stem cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity No
  • Available For Licensing Yes - Colorectal cancer; Liver cancer; Lung cancer; Ovarian cancer

Highest Development Phases

  • Discontinued Malignant melanoma

Most Recent Events

  • 25 Apr 2016 Caladrius Biosciences terminates a phase III trial for Malignant melanoma (late-stage disease) in USA (NCT01875653)
  • 08 Jun 2015 NeoStem is now called Caladrius Biosciences
  • 08 Jun 2015 Caladrius Biosciences initiates enrolment in the Intus trial for Malignant melanoma in USA (SC) (NCT01875653)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top